lanthanum carbonate has been researched along with Bone Diseases, Metabolic in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 7 (77.78) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Agapova, O; Fang, Y; Freedman, BI; Ginsberg, C; Hruska, KA; Malluche, H; Monier-Faugere, MC; Register, TC; Seifert, M; Sugatani, T | 1 |
Hanafusa, N | 1 |
Orita, H; Shigematsu, T; Tanaka, Y; Yamanaka, S; Yoshimoto, W | 1 |
Yokoyama, K | 1 |
Akizawa, T; Mizobuchi, M; Nakazawa, A | 1 |
Hamano, T | 1 |
Bruschetta, E; Cozzolino, M; Cusi, D; Galassi, A; Giovenzana, ME; Montanari, E | 1 |
Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
8 review(s) available for lanthanum carbonate and Bone Diseases, Metabolic
Article | Year |
---|---|
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Topics: Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Drug Discovery; Humans; Hyperphosphatemia; Japan; Lanthanum; Polyamines; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2015 |
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Chronic Disease; Contraindications; Dialysis; Diphosphonates; Fractures, Spontaneous; Kidney Diseases; Lanthanum; Minerals; Polyamines; Sevelamer | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic | 2010 |
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D | 2011 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D | 2012 |
Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
Topics: Animals; Bone Diseases, Metabolic; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
1 trial(s) available for lanthanum carbonate and Bone Diseases, Metabolic
Article | Year |
---|---|
CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Disease Models, Animal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Klotho Proteins; Lanthanum; Male; Mice, Inbred C57BL; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Wnt1 Protein | 2014 |